Genetic Disease & Complement Therapeutic Research Introduction

Q: What genetic disease and complement research services does Creative Biolabs provide?

Creative Biolabs provides variant-to-function study design, recombinant wild-type and variant protein work, expression and binding analysis, complement component and pathway assays, activation-product and deposition testing, cell-based phenotype studies, disease-model development, biomarker profiling, and complement-targeted candidate evaluation.

Q: Can you functionally evaluate a variant of uncertain significance in a complement gene?

Yes. A study can compare the variant with wild-type, benign, and known loss-of-function controls across expression, secretion, interaction, regulatory activity, pathway output, deposition, and cell-protection assays.

Q: What information is needed to design a customized study?

Useful information includes the gene and variant notation, reference transcript, disease phenotype, inheritance or clone context, prior genetic and complement data, available samples or constructs, preferred model, candidate information, benchmark, timeline, and the decision the study must support.

Genotype-Informed Complement Research

Turn a Genetic Finding into a Testable Complement Mechanism

Research support for programs in which sequence alone is not the endpoint

Creative Biolabs helps research teams determine whether a reported or newly identified variant changes complement protein abundance, secretion, binding, proteolytic activity, convertase control, surface protection, or terminal-pathway injury. The work can start from a curated gene list, a variant of uncertain significance, a patient-derived matrix, an engineered construct, or a complement-targeted therapeutic hypothesis.

Services are suited to target discovery, genotype–phenotype investigation, functional variant classification, biomarker strategy, translational model development, mechanism-of-action studies, lead comparison, and preclinical proof of concept. Rather than treating genetics and complement testing as separate workstreams, we align molecular evidence, pathway activity, disease phenotype, and candidate response around the decision your program must make.

Study plans can combine complement genetic testing, recombinant-variant production, complement function and activity testing, activation-fragment analysis, cell-based assays, and disease-relevant models.

Variant Prioritization

Choose variants and comparators using domain, population, phenotype, inheritance, and pathway context.

Functional Confirmation

Measure expression, interaction, regulation, cleavage, deposition, and pathway consequences.

Model Translation

Reproduce the defect in serum, cell, organoid, tissue, or in vivo systems with matched controls.

Therapeutic Decisions

Rank candidates by target engagement, pathway correction, phenotype rescue, and selectivity.

Have a complement variant but no validated functional consequence?

We can design a staged study that starts with protein and pathway confirmation before moving into complex disease models.

Request a Variant-to-Function Study Plan

Research Applications

Cover Distinct Genetic Routes to Complement Dysregulation

A pathogenic phenotype may arise from loss of a regulator, gain of an activator, impaired cell-surface protection, defective classical-pathway clearance, or a risk haplotype that becomes important only in a particular tissue or trigger context. Study design therefore follows the disease mechanism rather than a fixed test menu.

Complement-Mediated Thrombotic Microangiopathy

Evaluate CFH, CFI, CD46, C3, CFB, DGKE, and related findings in studies of alternative-pathway overactivation, endothelial injury, penetrance, trigger dependence, and response to terminal or proximal complement blockade.

Explore hemolytic uremic syndrome research

C3 Glomerulopathy and Complement-Driven Renal Disease

Connect variants or CFHR rearrangements with C3 consumption, convertase stability, factor H or factor I function, C3 fragment deposition, terminal activation, and renal-cell or matrix injury.

View C3b functional testing

Inherited and Complex Retinal Disease

Investigate CFH, CFI, C3, CFB, and CFHR risk or protective variants using binding, cofactor, cleavage, deposition, retinal-cell stress, and candidate-response assays relevant to complement-associated retinal pathology.

Explore factor H functional testing

Hereditary Angioedema and C1 Inhibitor Deficiency

Support SERPING1-centered research with antigenic and functional C1 inhibitor measurements, classical-pathway context, variant expression studies, and candidate rescue or replacement experiments.

Explore C1 inhibitor functional testing

GPI-Anchor Deficiency and Surface Protection

Model how PIGA or related defects alter CD55/CD59 display, C3-fragment deposition, membrane attack complex formation, complement-dependent cytotoxicity, hemolysis, and rescue by pathway-selective candidates.

View C5b-9 deposition assays

Complement Deficiencies and Polygenic Susceptibility

Study classical-pathway deficiencies, infection susceptibility, immune-complex clearance, autoimmune predisposition, risk haplotypes, modifier alleles, or project-defined disorders where genetic background shapes complement response.

Explore autoimmune disease research

Explore Complement Research by Disease Indication

Evidence Architecture

Build the Functional Chain from Genotype to Therapeutic Hypothesis

Variant studies are strongest when each experimental layer resolves a specific uncertainty. We select the shortest evidence path that can distinguish a true functional defect from altered expression, matrix artifacts, background genetics, or an unrelated disease process.

Prioritize the Variant

Define inheritance, domain location, conservation, allele frequency, phenotype concordance, and the reference sequence or isoform.

Establish Molecular Effect

Assess expression, secretion, stability, processing, multimerization, and interaction with complement partners or surfaces.

Resolve Pathway Function

Measure cofactor, decay acceleration, convertase, proteolysis, activation fragments, deposition, hemolysis, or receptor signaling.

Recreate Disease Context

Introduce the variant into relevant cells or proteins and apply triggers, serum matrices, patient samples, or tissue-specific stress.

Test Correction

Evaluate rescue by wild-type protein, reconstitution, pathway blockade, receptor modulation, gene-based tools, or lead candidates.

Controls that make interpretation defensible

Wild-type, known loss-of-function, and benign-variant comparators
Complement-depleted and reconstituted serum controls
Heat-inactivated serum and pathway-selective blockade
Matched expression or protein input across variants
Orthogonal biochemical and cell-based readouts
Rescue experiments to establish causality

Decisions the dataset can support

Whether a variant has a measurable complement effect
Which molecular function or pathway step is altered
Whether the defect is quantitative, qualitative, or context dependent
Which biomarker best tracks the functional consequence
Which target level offers a plausible intervention point
Whether the program is ready for candidate screening or advanced models

Need purified wild-type and variant complement proteins for direct comparison?

Protein generation, binding analysis, and functional assays can be coordinated under one experimental plan.

Explore Individual Complement Component Tests

Modular Research Capabilities

Select Assays by Mechanistic Question and Decision Threshold

Modules can be used independently for focused confirmation or linked into a tiered program. Concentrations, matrices, incubation times, complement sources, and controls are harmonized so results can be interpreted across assay levels.

Molecular

Expression, Secretion, and Protein Quality

Determine whether the variant changes the amount or biochemical state of the complement component.

mRNA and protein expression
Secretion and stability
Processing and cleavage
Purity, integrity, and aggregation

Interaction

Binding and Regulatory Interfaces

Quantify interactions that control amplification, convertase activity, ligand recognition, or surface protection.

ELISA and competition formats
SPR or BLI kinetics
C3b, factor H, factor I, CR1, or receptor binding
Surface and polyanion recognition

Enzymatic

Cofactor, Cleavage, and Convertase Control

Resolve loss or gain of regulatory activity beyond predicted structural impact.

Factor I-mediated C3b cleavage
Decay-acceleration assays
Convertase assembly and stability
SDS-PAGE and fragment immunoassays

Pathway

Complement Activation and Functional Output

Measure the net effect of a variant or candidate across classical, lectin, alternative, and terminal pathways.

CH50/AP50-style activity
C3a, C5a, Bb, C4d, and sC5b-9
Hemolysis and inhibition
Pathway-selective reconstitution

Surface

Deposition and Cell Protection

Test whether genetically altered control changes opsonization or membrane attack on disease-relevant surfaces.

C3b/iC3b and C4b deposition
C5b-9 membrane deposition
CD55/CD59-dependent protection
Cell viability and lysis

Translational

Biomarker and Genotype–Phenotype Integration

Align molecular findings with patient matrices, clinical phenotypes, triggers, and treatment-response hypotheses.

Serum or plasma profiling
Longitudinal and family-cohort comparisons
Multiplex biomarker panels
Integrated variant and functional reporting

Explore Complement Activation Product Testing

Experimental Context

Match the Model to the Variant, Tissue, and Complement Source

The same variant may appear neutral in a purified system yet become important on a vulnerable cell surface, under inflammatory stress, or in a serum background carrying additional risk alleles. Model selection therefore follows the proposed mechanism and the level of evidence required.

Purified and Reconstituted Systems

Wild-type and variant proteins, defined complement components, depleted sera, convertase assemblies, and biochemical surfaces for controlled mechanism studies.

Engineered and Patient-Derived Cells

Gene-edited lines, transfected cells, endothelial cells, erythroid cells, renal or retinal cells, iPSC-derived systems, and primary immune cells.

Co-culture, Organoid, and Tissue Models

Cell–cell interfaces, tissue-specific stress, extracellular matrix, organoid platforms, explants, and deposition-compatible surfaces.

Preclinical Disease Models

Model selection around complement genotype, species biology, disease trigger, tissue outcome, candidate exposure, pharmacodynamics, and rescue endpoints.

Sample types

SerumPlasmaWhole bloodCellsSupernatantPurified proteinDNA/RNATissue

Pre-analytical factors we plan around

Anticoagulant selection, collection-to-processing time, storage temperature, freeze–thaw history, ex vivo activation, hemolysis, species compatibility, endogenous inhibitor exposure, sample volume, batch effects, and the need for repeat or orthogonal analysis.

Unsure whether patient serum or a recombinant system should come first?

A feasibility phase can identify matrix effects and establish the most informative model sequence before scarce samples are committed.

Plan a Model Feasibility Study

Therapeutic Translation

Evaluate Whether a Candidate Corrects the Genetically Defined Defect

Candidate testing is designed to separate biochemical target engagement from pathway correction and true phenotype rescue. The result is a traceable decision path rather than a single inhibition value.

Gate 1 — Target engagement

Confirm binding, competition, component inhibition, receptor occupancy, or replacement of the missing activity.

Gate 2 — Pathway correction

Measure activation fragments, convertase control, deposition, hemolysis, or terminal-complex suppression in the variant context.

Gate 3 — Phenotype rescue

Demonstrate restoration of cell protection, endothelial behavior, tissue response, inflammatory balance, or disease-model outcome.

Gate 4 — Selectivity and window

Compare potency with cell health, residual host-defense activity, matrix dependence, donor variability, and benchmark performance.

Candidate formats and study outputs

Programs can compare complement-specific antibodies, recombinant regulators, replacement proteins, peptides, aptamers, small molecules, receptor antagonists, gene-silencing tools, editing concepts, or combination strategies.

Concentration–response curvesVariant-selective responseIC₅₀/EC₅₀ estimatesMechanism confirmationPharmacodynamic markersCandidate rankingCross-matrix comparisonGo/no-go criteria

Explore Complement Inhibitor Validation

Candidate discovery and assay development can also be combined through our complement component inhibitor development capabilities.

Need matched reagents for assay development?

Browse complement antibodies, proteins, inhibitors, and serum or plasma products for controls, reconstitution, and screening.

Explore Complement Research Products

Milestone-Based Execution

Advance from Variant Context to Decision-Ready Evidence

Each stage has a defined question, quality check, and progression criterion. Programs can stop after focused functional confirmation or continue through model development and therapeutic evaluation.

Research framing and evidence review

Define the gene, variant, inheritance or clone context, phenotype, proposed pathway effect, available material, comparator, candidate, and required decision.

Feasibility and assay qualification

Confirm reagent quality, matrix compatibility, dynamic range, complement activity, expression level, controls, and sample requirements.

Molecular and functional characterization

Run matched wild-type and variant studies across expression, binding, regulation, pathway activity, deposition, or cell-protection endpoints.

Disease-model and candidate testing

Transfer the validated defect into the selected cell, tissue, or preclinical model; establish dose, timing, pharmacodynamics, rescue, and benchmark comparison.

Integrated analysis and reporting

Deliver methods, QC, raw and processed data, statistical outputs, figures, variant-specific interpretation, candidate ranking, and next-step recommendations.

Request a Genetic Complement Research Proposal

Related Research

Studies Connecting Complement Variants to Functional Evidence

The selected research demonstrates why biochemical and pathway assays are needed after variant discovery, and how functional data can distinguish severe loss of regulation from subtle or context-dependent effects.

Locations and structural context of rare N-terminal complement factor H variants analyzed in aHUS, C3G, and AMD

CFH / aHUS / C3G / AMD

Functional characterization of rare N-terminal factor H variants

Wong and colleagues compared six CFH variants using protein production, C3b binding, surface plasmon resonance, cofactor assays, and hemolytic assays. The study illustrates how experimental evidence can separate a profound defect from subtle or undetectable functional changes.

View research via DOI
CC BY 4.0

Complement factor I domain structure and genetic variants selected for functional evaluation

CFI / cofactor activity / functional assays

Functional evaluation of complement factor I variants by orthogonal assays

Gerogianni and colleagues assessed eight recombinant factor I variants with SDS-PAGE, ELISA, and a Luminex bead-based surface assay using factor H or soluble CR1 as cofactors. The work shows why assay context and multiple readouts matter when variant effects are modest.

View research via DOI
CC BY 4.0

SERPING1 gene structure and mutations identified in families with hereditary angioedema

SERPING1 / hereditary angioedema / C1 inhibitor

A nationwide hereditary angioedema study identified novel SERPING1 mutations

Rijavec and colleagues combined clinical and complement measurements with sequencing and copy-number analysis in families with hereditary angioedema. The study highlights genetic heterogeneity and the value of pairing a molecular finding with C1 inhibitor level and function.

View research via DOI
CC BY

Explore Complement Genetic Testing Services

Questions and Answers

Frequently Asked Questions

What genetic disease and complement research services does Creative Biolabs provide?

We provide variant-to-function study design, recombinant wild-type and variant protein work, expression and binding analysis, complement component and pathway assays, activation-product and deposition testing, cell-based phenotype studies, disease-model development, biomarker profiling, and complement-targeted candidate evaluation.

Can you functionally evaluate a variant of uncertain significance in a complement gene?

Yes. The study can compare the variant with wild-type, benign, and known loss-of-function controls across expression, secretion, interaction, regulatory activity, pathway output, deposition, and cell-protection assays. The final panel depends on the protein domain, proposed mechanism, disease context, and available evidence.

Which complement genes and mechanisms can be studied?

Programs may address CFH, CFI, C3, CFB, CD46, SERPING1, CFHR genes, PIGA-related surface protection, classical-pathway deficiencies, or other project-defined genes. Mechanisms can include quantitative deficiency, impaired cofactor or decay activity, convertase stabilization, altered receptor signaling, defective membrane protection, or abnormal terminal-pathway activation.

Can genetic testing be combined with functional complement assays?

Yes. Complement genetic testing can be linked with protein-level analysis, pathway activity, activation products, deposition, hemolysis, receptor or ligand interaction, and disease-relevant cell assays. This integrated approach helps determine whether a genetic finding has a measurable biological consequence.

Can you work with patient serum, plasma, or cells?

Yes, subject to sample suitability, consent, and project requirements. Feasibility planning considers anticoagulant, processing time, storage, freeze–thaw history, ex vivo complement activation, matrix interference, sample volume, and the controls required to distinguish genotype-associated effects from pre-analytical variation.

Can you compare therapeutic response across wild-type and variant backgrounds?

Yes. Candidates can be assessed for target engagement, pathway correction, deposition or hemolysis inhibition, phenotype rescue, selectivity, and dose response in matched wild-type and variant systems. Rescue with wild-type protein or pathway-selective controls can strengthen causal interpretation.

What information is needed to design a customized study?

Please share the gene and variant notation, reference transcript, disease phenotype, inheritance or clone context, prior genetic and complement data, available samples or constructs, preferred model, candidate information, benchmark, timeline, and the decision the study must support. If the mechanism is uncertain, we can begin with a focused feasibility phase.

Ask About a Genetic Complement Research Project

Scientific Literature

References

Wong, Edwin K. S., et al. “Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD.” Frontiers in Immunology, vol. 11, 2021, article 602284. https://doi.org/10.3389/fimmu.2020.602284
Gerogianni, Alexandra, et al. “Functional Evaluation of Complement Factor I Variants by Immunoassays and SDS-PAGE.” Frontiers in Immunology, vol. 14, 2023, article 1279612. https://doi.org/10.3389/fimmu.2023.1279612
Rijavec, Matija, et al. “Hereditary Angioedema Nationwide Study in Slovenia Reveals Four Novel Mutations in SERPING1 Gene.” PLOS ONE, vol. 8, no. 2, 2013, e56712. https://doi.org/10.1371/journal.pone.0056712